Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US EUA For Lilly’s Bamlanivimab Conditioned On Additional GMP Compliance Requirements

Nov 10 2020

• By Bowman Cox

Coronavirus — fda balances quality against availability of covid-19 neutralizing antibody

Related Content

US Buy Of Lilly’s COVID-19 Therapy Now Turns On FDA's Manufacturing Quality Assessment

Oct 29 2020

Related Companies

Eli Lilly and Company

Additional Topics

United States Manufacturing Quality Compliance Coronavirus COVID-19 BioPharmaceutical

More from Manufacturing

More from Compliance

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window